Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Varivax in Pediatric Solid Organ Transplant Candidates
NCT00213304Phase 3Completed
- Sponsor
- SickKids
- Start
- Jun 1999
- Primary completion
- Dec 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of varicella virus vaccine live in varicella (VZV), sponsored by SickKids. Primary endpoints: Determination of the safety of VARIVAX at 6 months and Proportion immunized who demonstrate seroconversion and maintain humoral immunity at 24 months. Started Jun 1999; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT00213304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00213304.